Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome

Lancet

Volumn 349, Issue 9047, 1997, Pages 225-230

  Hughes, R A C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSISTED VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; ERYTHEMA; FEVER; FOLLOW UP; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MENINGISM; MULTICENTER STUDY; MYALGIA; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; THORAX PAIN; TREATMENT OUTCOME; VOMITING; WALKING;

EID: 0031034253     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09095-2     Document Type: Article

References (18)

1. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.
2. French Cooperative group in plasma exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.
3. Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-29.
4. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 872-75.
5. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43: 1034-36.
6. Hartung H-P, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome -part 1. Muscle Nerve 1995; 18: 137-53.
7. Hartung H-P, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome -part 1. Muscle Nerve 1995; 18: 154-64.
8. Voltz R, Hohlfeld R. The use of intravenous immunoglobulins in the treatment of neuromuscular disorders. Curr Opin Neurol 1996; 9: 360-66.
9. Vriesendorp FJ, Mayer RF, Koski CL. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis. Arch Neurol 1991; 48: 858-61.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 1977; 35: 1-39.
11. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988; 28: 347-53.
12. Bril V, Use WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996; 46: 100-03.
13. Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 1988; 23: 354-59.
14. Palace J, Hughes R. Guillain-Barré syndrome with severe persistent disability: relationship to hyperacute Guillain-Barré syndrome. Eur J Neurol 1994; 1: 21-27.
15. Rees JH, Soudain SE, Gregson NA, Hughes RAC. A prospective case control study to investigate the relationship between Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-79.
16. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586-90.
17. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy: I clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988; 51: 605-12.
18. Oomes PG, van der Meché FGA, Kleyweg RP, et al. Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Neurology 1996; 46: 96-100.